Ocuphire Pharma has filed a patent for a method of synthesizing highly pure phentolamine mesylate using phentolamine, methanesulfonic acid, acetone, and water. The invention aims to provide a more efficient and effective process for producing this compound. GlobalData’s report on Ocuphire Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ocuphire Pharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ocuphire Pharma, cancer treatment biomarkers was a key innovation area identified from patents. Ocuphire Pharma's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Synthesis of highly pure phentolamine mesylate

Source: United States Patent and Trademark Office(USPTO). Credit: Ocuphire Pharma Inc

Phentolamine mesylate, a medication used to treat high blood pressure and certain heart conditions, is the subject of a filed patent (Publication Number: US20230146674A1). The patent claims specify the composition of phentolamine mesylate, particularly in terms of its water content and impurities.

Claims 51 to 54 state that the phentolamine mesylate comprises 0% to about 6% water by weight, with a preference for a lower water content of about 0% to 3% or 0% to 2%. Additionally, the phentolamine mesylate should contain less than 0.3% of another impurity by weight, with a further preference for less than 0.1% of the impurity.

Claim 55 specifies that the impurity in question is Compound 1, while claim 56 states that the impurity can be an alkyl methanesulfonate. Claim 57 expands the list of potential impurities to include N-(2-aminoethyl)-2-[(3-hydroxyphenyl)(4-methylphenyl)amino]-acetamide, 2-chloromethyl-4,5-dihydro-1H-imidazole, or 3-hydroxy-4'-methyldiphenylamine, or a salt thereof.

These claims provide specific guidelines for the composition of phentolamine mesylate, ensuring that it contains a controlled amount of water and impurities. By setting limits on the water content and impurity levels, the patent aims to establish a standard for the quality and purity of phentolamine mesylate.

Phentolamine mesylate is commonly used in medical settings to manage conditions such as hypertension and certain heart conditions. The patent claims outlined in this publication seek to protect a specific formulation of phentolamine mesylate, ensuring that it meets certain quality standards in terms of water content and impurity levels. This patent may have implications for pharmaceutical companies involved in the production and distribution of phentolamine mesylate, as it establishes a specific composition that must be adhered to in order to avoid infringement. Overall, this patent aims to contribute to the development of safe and effective medications for the treatment of high blood pressure and heart conditions.

To know more about GlobalData’s detailed insights on Ocuphire Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies